Amgen
Executive Summary
D.C. Circuit Court upholds April 1989 ITC ruling dismissing Amgen complaint that Chugai's importation of erythropoietin into the U.S. constitutes an unfair trade practice. The appeals court also affirmed an earlier ITC decision that found the importation of EPO by Chugai did not infringe Amgen's patent.